Financial Performance - The company's revenue for the year ended December 31, 2025, was HKD 73,503,000, representing an increase of 4.2% from HKD 70,509,000 in 2024[4] - Gross profit for the year was HKD 7,726,000, compared to a gross loss of HKD 4,940,000 in the previous year, indicating a significant turnaround[4] - The net loss for the year was HKD 80,841,000, a reduction of 67.9% from a net loss of HKD 251,854,000 in 2024[5] - Revenue from medical laboratory testing and health check services was HKD 35,782,000 in 2025, a decrease of 3.5% from HKD 39,158,000 in 2024[23] - Insurance brokerage service revenue increased to HKD 37,570,000 in 2025, up 22.5% from HKD 30,600,000 in 2024[23] - The company reported a total loss of approximately HKD 80,841,000 for the year ending December 31, 2025[15] - The total loss before tax for the year ended December 31, 2025, was HKD 81,697,000, with a net loss of HKD 80,841,000 after tax credits[27] - The company’s annual loss for 2025 was HKD 68,778,000, a reduction from a loss of HKD 198,146,000 in 2024, indicating an improvement of approximately 65.3%[37] Assets and Liabilities - Total assets increased to HKD 702,575,000 in 2025, up from HKD 529,955,000 in 2024, reflecting a growth of 32.6%[6] - The total liabilities increased to HKD 546,830,000, up from HKD 287,567,000, representing an increase of 90%[7] - The equity attributable to the owners of the company decreased to HKD 191,410,000 from HKD 264,942,000, a decline of 27.7%[7] - As of December 31, 2025, the company's current liabilities exceeded its current assets by approximately HKD 266,069,000[15] - The total borrowings and lease liabilities were approximately HKD 338,012,000 and HKD 12,620,000, respectively, with cash and bank balances of about HKD 12,083,000[15] - The total assets as of December 31, 2025, amounted to HKD 702,575,000, with significant contributions from non-current assets in mainland China at HKD 571,984,000[31] - The total liabilities as of December 31, 2025, were HKD 546,830,000, with significant liabilities in the boron neutron capture therapy segment at HKD 227,889,000[27] Cash Flow and Financing - The company's cash and cash equivalents decreased to HKD 12,083,000 from HKD 18,913,000, a decline of 36.4%[6] - The company believes it will have sufficient working capital to meet its operational needs and financial obligations for the foreseeable future[16] - The company raised $35,000,000 (equivalent to HKD 272,440,000) through the issuance of convertible bonds to a subscriber, with the bonds maturing in four years[19] - The company secured a loan of up to RMB 180,000,000 from Hainan Rural Commercial Bank for operational purposes, guaranteed by the company and its chairman[75] - The company obtained bank loans of approximately HKD 141,087,000 as of December 31, 2025, significantly increased from HKD 13,259,000 in 2024[95] Operational Highlights - The company is engaged in providing medical laboratory testing services and health check services in Hong Kong, and cancer immunotherapy and health management services in China[13] - The company is also involved in the sale and distribution of health-related and pharmaceutical products in China and Hong Kong[13] - The company has committed to constructing and operating a cancer treatment center utilizing the NeuCure® boron neutron capture therapy system, with construction entering its final stages and expected to be ready for trial operations in Q1 2026[62] - The company plans to initiate the second phase of clinical trials for its LY007 cell injection product by the end of 2026, which is the first CAR-T therapy approved for clinical trials in China targeting CD20[60] - The company has strategically decided to reallocate resources from the sales and distribution of healthcare-related and pharmaceutical products to higher-margin and higher-growth segments, such as boron neutron capture therapy[61] Research and Development - Research and development costs were reduced to HKD 17,201,000 from HKD 33,309,000, a decrease of 48.3%[4] - The company recorded a net foreign exchange gain of HKD 7,700,000 in 2025, a recovery from a loss of HKD 11,152,000 in 2024[24] - The company confirmed impairment losses of approximately HKD 52,713,000 related to boron neutron capture therapy equipment damaged in a storm, with insurance claims recognized as compensation income[24] - The group recorded an impairment loss of approximately HKD 6,731,000 for right-of-use assets in fiscal year 2025 due to new lease agreements for the operations of DVF Group[70] Corporate Governance - The company is listed on the GEM of the Hong Kong Stock Exchange[14] - The financial statements are prepared in accordance with applicable Hong Kong Financial Reporting Standards[15] - The audit committee has reviewed the consolidated financial statements for the fiscal year 2025[106] - The company and its subsidiaries did not purchase, sell, or redeem any listed securities during the fiscal year ending December 31, 2025[109] - The board of directors has undergone changes, with Dr. Yin Ye appointed as an executive director and Dr. Zhang Xiao appointed as an independent non-executive director[105] Market Position and Future Outlook - The year 2025 is identified as a critical year for the company, with significant breakthroughs in its core businesses of boron neutron capture therapy and CAR-T, laying a solid foundation for future growth[81] - The boron neutron capture therapy center in Hainan is set to begin trial operations in February 2026, serving as a demonstration center and a cornerstone for a national network of treatment centers[81] - The CAR-T division has launched China's first clinically approved CD20-targeted CAR-T therapy, marking a significant step towards commercialization, with positive clinical data supporting its efficacy and safety[82]
中国生物科技服务(08037) - 2025 - 年度业绩